Epha5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers

HIGHLIGHTS

• who: Zhenxiang Li from the (UNIVERSITY) have published the research: EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers, in the Journal: (JOURNAL)
• what: Both the studies showed the beneficial effects of atezolizumab as compared to docetaxel in patients with NSCLCs and showed that the improvement in survival was also correlated with the PD-L1 expression. The studies focused on the importance of assessing PD-L1 expression using immunohistochemistry as a predictive biomarker to select the patients for atezolizumab treatment as a second-line treatment. This . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.